Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.8 SAR | +0.30% | -0.15% | -3.80% |
05-08 | Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Nahdi Medical Logs Lower Q1 Net Profit; Revenue Rises | MT |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.80% | 4.57B | D- | ||
-53.68% | 10.44B | B- | ||
-45.65% | 8.68B | B | ||
-26.18% | 6.45B | B | ||
-7.49% | 5.98B | C+ | ||
+85.61% | 4.91B | C | ||
+5.73% | 4.49B | B | ||
-26.42% | 4.1B | C | ||
-18.65% | 2.58B | C- | ||
+161.11% | 2.54B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4164 Stock
- Ratings Nahdi Medical Company